公开(公告)号：US20240208956A1

公开(公告)日：2024-06-27

申请号：US18286037

申请日：2022-04-07

Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.

Inventor： Chang Sik Lee ,  Jung Taek Oh ,  Hyeseung Song ,  Hyunjin Michael Kim

IPC: C07D413/14 ,  A61K31/4245 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/5377 ,  C07D413/12 ,  C07D417/14 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

CPC classification number: C07D413/14 ,  A61K31/4245 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/5377 ,  C07D413/12 ,  C07D417/14 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

Abstract: The present invention relates to a novel 1,3,4-oxadiazole thiocarbonyl compound having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof for preparing a medicament, a pharmaceutical composition containing the same, a therapeutic method using the composition, and a preparation method thereof, wherein a novel compound having a selective HDAC6 inhibitory activity is represented by formula I.

公开(公告)号：US20240208923A1

公开(公告)日：2024-06-27

申请号：US18281138

申请日：2022-03-09

Applicant: Jnana Therapeutics Inc.

Inventor： Dean G. Brown ,  Jaclyn L. Henderson ,  Giovanni Muncipinto ,  Joshua E. Zweig ,  Long V. Nguyen ,  Nicholas Pullen ,  Mitchell T. Antalek ,  Ryan A. Hollibaugh

IPC: C07D401/04 ,  A61K31/44 ,  A61K31/4523 ,  A61K31/4525 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D211/58 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/06 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D401/04 ,  A61K31/44 ,  A61K31/4523 ,  A61K31/4525 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D211/58 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/06 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.

公开(公告)号：US20240207281A1

公开(公告)日：2024-06-27

申请号：US18556566

申请日：2022-04-20

Applicant: CELGENE CORPORATION ,  BRISTOL-MYERS SQUIBB COMPANY

Inventor： Poliana Alves PATAH ,  Michael POURDEHNAD ,  Xinyu WEI ,  Dimitrios ZARDAVAS

IPC: A61K31/5377 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/5377 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/3955 ,  A61P35/00

Abstract: Provided herein are methods of using 2-(2.6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1, 3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or an equivalent thereof for treating, preventing or managing B-cell lymphoma.

公开(公告)号：US20240207202A1

公开(公告)日：2024-06-27

申请号：US18534114

申请日：2023-12-08

Applicant: The Wistar Institute of Anatomy and Biology

Inventor： Gao Zhang ,  Qin Liu ,  Dario Carlo Altieri ,  Meenhard Herlyn

IPC: A61K31/06 ,  A61K31/155 ,  A61K31/245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/713 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K31/06 ,  A61K31/155 ,  A61K31/245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C12Q1/6886 ,  G01N33/5743 ,  A61K31/713 ,  A61K2300/00 ,  C12Q2600/158 ,  G01N2800/44 ,  G01N2800/60 ,  G01N2800/7028

Abstract: Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

公开(公告)号：US20240199620A1

公开(公告)日：2024-06-20

申请号：US18389182

申请日：2023-11-13

Applicant: RAPT THERAPEUTICS, INC.

Inventor： Hilary Plake Beck ,  Berenger Biannic ,  Minna Hue Thanh Bui ,  Dennis X. Hu ,  John Michael Ketcham ,  Jay Patrick Powers ,  Maureen Kay Reilly ,  Omar Robles-Resendiz ,  Hunter Paul Shunatona ,  James Ross Walker ,  David Juergen Wustrow ,  Ashkaan Younai ,  Mikhail Zibinsky ,  Jeffrey J. Jackson

IPC: C07D487/04 ,  A61K31/122 ,  A61K31/198 ,  A61K31/235 ,  A61K31/42 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7135 ,  A61K31/728 ,  A61K45/06

CPC classification number: C07D487/04 ,  A61K31/122 ,  A61K31/198 ,  A61K31/235 ,  A61K31/42 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7135 ,  A61K31/728 ,  A61K45/06

Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

公开(公告)号：US20240199587A1

公开(公告)日：2024-06-20

申请号：US18490967

申请日：2023-10-20

Applicant: Hoffmann-La Roche Inc.

Inventor： Machoud AMOUSSA ,  Joerg BENZ ,  Niels Kevin BRIAN ,  Kallie FRISTON ,  Maude GIROUD ,  Uwe GRETHER ,  Katrin GROEBKE ZBINDEN ,  Benoit HORNSPERGER ,  Carsten KROLL ,  Bernd KUHN ,  Camiel John LEAKE ,  Rainer E. MARTIN ,  David Friedrich Erhard NIPPA ,  Fionn Susannah O’HARA ,  Bernd PUELLMANN ,  Hans RICHTER ,  Martin RITTER ,  Didier ROMBACH ,  Philipp Claudio SCHMID ,  Shounan ZHANG

IPC: C07D403/14 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/14 ,  C07D407/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10 ,  C07D487/10 ,  C07D491/052

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/14 ,  C07D407/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10 ,  C07D487/10 ,  C07D491/052

Abstract: The invention provides new heterocyclic compounds having the general formula (I)




wherein A, B, X, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

公开(公告)号：US20240199572A1

公开(公告)日：2024-06-20

申请号：US18280531

申请日：2022-03-15

Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： Gregory R. THATCHER ,  Cutler T. LEWANDOWSKI ,  Manel BEN AISSA ,  Brian LAYDEN ,  Yeng-Jeng SHAW ,  Ganga Reddy VELMA ,  Mary Jo LADU

IPC: C07D333/40 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/4436 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/69 ,  A61P3/10 ,  A61P25/28 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07F5/02

CPC classification number: C07D333/40 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/4436 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/69 ,  A61P3/10 ,  A61P25/28 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07F5/025

Abstract: Compounds that induce expression of ATP-binding cassette transporter A1 (ABCA1) without lipogenesis are provided, as are methods of using the same to treat or prevent type 2 diabetes or dementia.

公开(公告)号：US20240197747A1

公开(公告)日：2024-06-20

申请号：US18540628

申请日：2023-12-14

Applicant: AcuraStem, Inc.

Inventor： Justin K. ICHIDA ,  Matthew STREMLAU ,  Hongyan ZHOU

IPC: A61K31/5377 ,  A61K31/155 ,  A61K31/245 ,  A61P31/14

CPC classification number: A61K31/5377 ,  A61K31/155 ,  A61K31/245 ,  A61P31/14

Abstract: The present invention relates to methods of treating viral infections including COVID-19 and compositions with a combination of (i) an inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) and (ii) an inhibitor of transmembrane serine proteinase 2 (TMPRSS-2).

公开(公告)号：US20240197715A1

公开(公告)日：2024-06-20

申请号：US18510836

申请日：2023-11-16

Applicant: NOVARTIS AG

Inventor： Rita ANDRAOS-REY ,  Sandra BLUM-KALLERT ,  Marta CORTES-CROS ,  Ruben DE KANTER ,  Stephane FERRETTI ,  Isabel Cristina Colaco Farias JACO ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Laurent LABORDE ,  Henrik MOEBITZ ,  Michele MOSCHETTA ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG

IPC: A61K31/4745 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/243 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/243 ,  A61P35/00

Abstract: The present invention provides a pharmaceutical combination comprising a WRN inhibitor in combination with at least one additional therapeutically active agent. It also provides a method of treating cancer, involving administering to a subject in need thereof the WRN inhibitor in combination with the at least one additional therapeutically active agent. For example, the WRN inhibitor compound, or a pharmaceutically acceptable salt thereof, is of formula (I):




wherein R1, R2, R3, R4, R5, R28, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein.

公开(公告)号：US12011448B2

公开(公告)日：2024-06-18

申请号：US17056931

申请日：2019-05-24

Applicant: Japan Tobacco Inc.

Inventor： Yoshifumi Ueda ,  Takafumi Kurimoto

IPC: A61K31/5377 ,  A61P13/12

CPC classification number: A61K31/5377 ,  A61P13/12

Abstract: The present invention provides a therapeutic agent or prophylactic agent for nephrotic syndrome, containing N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.